Preliminary Effects of Hydrogen-Oxygen Inhalation on Nodule Size, IL-6, and Neutrophils in Patients with Small Pulmonary Nodules.
Xiaohui Wei, Wei Zhang, Yuanyuan Li, Xiaojuan Sha, Hongpeng Yi, Chao Cui · Drug design, development and therapy · 2026
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In the smoking subgroup, IL-6 level and neutrophil count also decreased significantly after hydrogen-oxygen inhalation (both P<0.01), while CRP remained relatively stable. These findings add human evidence supporting molecular hydrogen's therapeutic potential to influence inflammatory regulation.
What the Findings Mean
H2HUBB reviewed how molecular hydrogen affected the outcomes measured in 59 patients. In the smoking subgroup, IL-6 level and neutrophil count also decreased significantly after hydrogen-oxygen inhalation (both P<0.01), while CRP remained relatively stable.
What the Researchers Studied
The researchers studied 59 patients. The study used a randomized human clinical trial. The comparison condition was control condition or baseline measurements.
What Effects Did Molecular Hydrogen Have?
Source-reported hydrogen concentration: 66.6% source-reported H₂ gas concentration; Source-reported hydrogen exposure: 66.6% source-reported H₂ gas concentration; 3000 mL/min total gas flow (approximately 1998 mL/min H₂ component); reported treatment duration: 14 days. In the smoking subgroup, IL-6 level and neutrophil count also decreased significantly after hydrogen-oxygen inhalation (both P<0.01), while CRP remained relatively stable. The authors concluded that within the limitations of this single-center, small-sample study with a 3-month follow-up, hydrogen-oxygen inhalation can reduce SPN diameter and downregulate peripheral blood IL-6 and neutrophil levels, exerting a targeted anti-inflammatory effect especially in smoking patients.
Why These Findings Matter
These findings add human evidence supporting molecular hydrogen's therapeutic potential to influence inflammatory regulation and contribute to the growing body of molecular-hydrogen research.
How Strong Is This Evidence?
This is human clinical evidence from a randomized human clinical trial. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as human clinical study with human clinical evidence. The research population or model was 59 patients. The reported sample size was 59. The study used a randomized human clinical trial. The source-reported hydrogen concentration was 66.6% source-reported H₂ gas concentration. The reported treatment duration was 14 days.
Limitations and Safety
Reported limitations: Within the limitations of this single-center, small-sample study with a 3-month follow-up, hydrogen-oxygen inhalation can reduce SPN diameter and downregulate peripheral blood IL-6 and neutrophil levels, exerting a targeted anti-inflammatory effect especially in smoking patients. The smoking subgroup consisted of 14 patients in the observation group and 16 patients in the control group, and the relatively small sample size of this subgroup may limit the statistical power for detecting between-group differences.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.